The Effect of Tranexamic Acid on the Outcome of Total Ankle Replacement

Mohammed Ali 1, Abdalla Hassan 1, Smit Shah 1, Anjum Rashid 2, Ashraf Naguib 1

1. Trauma and Orthopaedics, North Cumbria Integrated Care NHS Foundation Trust, Carlisle, GBR 2. Trauma and Orthopaedics, The James Cook University Hospital, Middlesbrough, GBR

Corresponding author: Mohammed Ali, mohammedkhider84@hotmail.com

Abstract

Background: Infection rates after total ankle replacement (TAR) are known to be greater than those after hip or knee arthroplasty. Swelling after TAR can make wound healing more difficult, which can lead to infection. Tranexamic acid (TXA) has been shown to minimize blood loss after surgery, improving healing outcomes. We aim to assess the effect of TXA on blood loss and wound complications in TAR.

Methods: The research looked retrospectively at patients who had TAR procedures between September 2014 and December 2019. The procedures were done using the anterior approach at a single hospital by two, foot and ankle surgeons. Tranexamic acid was given intraoperatively before the tourniquet was inflated. The surgeons did not use surgical drains. Pre and postoperative hemoglobin levels, outcome scores as well as post-operative complications were all documented.

Results: A total of 69 patients were included in the study with 33 of them receiving TXA. With a mean age of 67.2, we had 31 females and 38 males. Tranexamic acid was given in doses ranging from 1 gm to 2 gm. None of the patients required blood transfusions after surgery, and there was no statistically significant difference in pre and postoperative hemoglobin levels between the two groups. In the TXA group, there were fewer wound complications. The TXA group achieved better results compared to the non-TXA group (p=0.0130).

Conclusion: Tranexamic acid is safe and effective in lowering postoperative bleeding and preserving hemostasis after deflating the tourniquet, reducing edema and postoperative wound problems such as breakdown and dehiscence.

Categories: Preventive Medicine, Infectious Disease, Orthopedics
Keywords: wound complication, transfusion rate, postoperative wounds, tranexamic acid, total ankle arthroplasty

Introduction

For a high number of patients with considerable joint damage, total ankle replacement (TAR) has become a viable surgical option [1]. Because it gives a good range of motion and facilitates early mobilization, TAR has been demonstrated to overcome the previous challenges associated with fusion [2]. Furthermore, TAR has a faster rehabilitation course and considerably higher functional outcomes, particularly in young, high-demand patients [3]. However, compared to hip or knee arthroplasty, the incidence of infection, nerve injury, implant loosening, and periprosthetic fracture cannot be regarded as minimal [4]. Infections after total hip or knee replacement have been observed in up to 3% of patients, whereas profound infection rates after total ankle arthroplasty (TAR) has been reported to be as high as 13% in a recent meta-analysis [4,5]. Impaired wound healing can result in a deep infection, which is a life-threatening condition [6]. Insufficient blood flow in the wound margins due to an improper skin incision or severe soft tissue dissection are two common causes of wound healing difficulties.

Furthermore, a large amount of swelling might cause skin necrosis, leading to infection [7]. The management of perioperative blood loss, specifically postoperative hemarthrosis, is a controllable factor affecting patient recovery, complication rates, and hospital expenses, according to a review of the literature on total knee and total hip arthroplasty (TKA) and total hip arthroplasty (THA) [8]. Drain output has been utilized to determine the amount of blood that has accumulated intra-articularly. Reduced drain output indicates a reduction in hemarthrosis, which could help relieve pressure on the wound and reduce wound problems [9]. Anti-fibrinolytic drugs like tranexamic acid (TXA) help reduce blood loss, postoperative soakage, seroma, and swelling in patients who have both normal and excessive fibrinolytic responses to surgery and trauma, reducing the risk of postoperative or post-injury problems [10,11,12]. Tranexamic acid is a synthetic lysine derivative with a molecular weight of 157 g/mol that uses a reversible interaction with plasminogen and the active protease, plasmin, to exert its anti-fibrinolytic function [13]. Tranexamic acid can be administered through both intravenous or topical/infiltration routes, and most published research revealed both ways to be effective [13]. At the cellular level, fibrin is constantly deposited and eliminated by fibrinolytic mechanisms. Tranexamic acid inhibits proteolytic degradation of fibrin by blocking the attachment of plasminogen and plasmin [14]. Ivana et al. [15] have previously shown, in skin wounds, that...
anti-fibrinolytic agents increase collagen synthesis and tensile strength within granulation tissue, presumably by preserving the fibrin matrix. Additionally, Vinckier et al.’s study concluded that TXA could accelerate normal wound healing by stabilizing the fibrin structures within the non-collapsible dental socket [16].

In this case series, we investigate the effect of TXA in ankle arthroplasty, comparing the results of those who received TXA to the group who did not. We report the blood loss and the postoperative wound complications. This case series has been reported in line with the ‘participation responsibility openness commitment experimentation sensitivity sense’ (PROCESS) criteria [17].

**Materials And Methods**

This was a retrospective study that did not require Institutional Review Board/ethics committee approval. Data was collected from the operative theatre records, patient notes, outpatient clinic letters, and the Picture Archiving and Communication System (PACS) version 6 (Centricity, GE Healthcare, Chicago, USA) for image evaluation. Patients with incomplete clinical records were excluded from the study. A retrospective analysis was conducted on 69 consecutive patients who underwent TAR surgeries with the Integra® and Cadence® total ankle prosthesis between September 2014 and December 2019. All surgeries were performed at one institution by two, foot and ankle surgeons through the anterior approach. Intraoperatively, TXA was given before tourniquet inflation. The surgeons did not use any form of surgical drains. We recorded patients’ demographics, co-morbidities, type of anaesthesia, dose of TXA, preoperative and postoperative hemoglobin levels, indications for surgery, surgical procedures, wound complications, and postoperative complications.

To assess functional outcomes, the Manchester-Oxford foot questionnaires (MOXFQ) were recorded perioperatively and postoperatively. The MOXFQ patient-reported outcomes (PROs) are a set of 16 self-administered, paper-based assessments [18]. Walking/standing, pain, and social interaction are the three domains measured by the PROs. Patients react on a five-point Likert scale ranging from no limitation to extreme limitation. Each domain’s score is derived by adding the replies to each item within that domain. The raw scores can be translated to a 0 to 100 scale, with 100 being the most significant. All complications were documented. Wound infection, deep infection, aseptic loosening, malalignment, nerve or tendon injury, venous thromboembolism, and periarticular fracture are significant problems. Minor complications were noted, including stiffness, loose bodies, and heterotopic ossification. Our definition of revision is "any surgery leading to exchange or removal of any prosthetic component except for the incidental exchange of the polyethylene insert in a movable bearing (three-component) ankle replacement," as proposed by Henricson et al. [19].

The statistical package for social science (SPSS) version 24.0 (IBM Corp., Armonk, NY, USA) was used to analyze demographic data with descriptive statistics.

**Results**

Sixty-nine patients with complete records were included in the study, including 31 females and 38 males. Thirty-three received TXA, while 36 did not. The mean age was 67.2 years (standard deviation (SD)=10.16). Indications of surgery were recorded as failed fusion in five patients, post-traumatic arthritis in 18 patients, and rest as osteoarthritis. Cadence implants were used in 43 patients, and 26 had Integra TAR. The anesthetics varied between general and spinal, and the popliteal block was recorded in only six patients. The dose of TXA varied between 1 gm and 2 gm. The preoperative and postoperative hemoglobin levels, indications for surgery, surgical procedures, wound complications, and postoperative complications are reported in Table 1 and Table 2. None of the patients required blood transfusion postoperatively. No cases of deep venous thrombosis or pulmonary embolisms were reported.

|          | Preoperative Hb | Postoperative Hb |
|----------|----------------|-----------------|
| TXA      | 138.3 (SD 11.9) | 128.1 (SD 9.87) |
| Non-TXA  | 138.6 (SD 13.8) | 127 (SD 15.5)   |
| P-value  | 0.9236          | 0.7289          |
| 95% Confidence interval | -6.5186 to 5.9186 | -5.2093 to 7.4093 |

**TABLE 1: Preoperative and postoperative hemoglobin**

TXA: Tranexamic acid, SD: Standard deviation
### TABLE 2: Patients who developed wound complications

OA: Osteoarthritis, GERD: Gastroesophageal reflux disease, GA: General anesthesia, NPWT: Negative pressure wound therapy, HTN: Hypertension, NIDDM: Non-insulin-dependent diabetes mellitus, DM: Diabetes mellitus, COPD: Chronic obstructive pulmonary disease

| Age/Sex | PMH | Anesthetics | TXA | Preop Hb | Postop Hb | Indication | Postop complication | Management |
|---------|-----|-------------|-----|----------|-----------|------------|---------------------|------------|
| 63/M    | OA  | GA          | No  | 140      | 128       | OA         | Delayed wound healing | Observed  |
| 63/M    | Depression | Spinal | No  | 122      | 116       | Post-traumatic OA | Delayed wound healing | Observed  |
| 76/F    | HTN, NIDDM, Hypothyroid | Spinal | No  | 139      | 124       | OA         | Deep Infection       | Washout/IV antibiotics |
| 52/M    | DM  | GA          | No  | 174      | 173       | OA, Failed fusion | Superficial infection | Oral antibiotics |
| 70/M    | GERD | Spinal      | No  | 149      | 131       | Post-traumatic OA | Delayed wound healing | Observed  |
| 62/F    | COPD, Smoker | Spinal | No  | 136      | 120       | Post-traumatic OA | Superficial infection | Oral antibiotics |
| 56/F    | Asthma | GA          | No  | 136      | 118       | OA         | Wound dehiscence     | NPWT       |
| 40/F    | Fit and well | GA      | No  | 126      | 120       | Post-traumatic OA | Wound dehiscence     | Observed  |
| 57/F    | Learning difficulty | GA      | Yes: 1 gm | 133     | 122       | OA         | Wound dehiscence     | Observed  |
| 75/M    | OA  | Spinal      | Yes: 2 gm | 131     | 127       | OA         | Wound dehiscence     | NPWT       |
| 77/M    | Fit and well | Spinal  | Yes: 1.5 gm | 143    | 120       | OA         | Superficial infection | Oral antibiotics |

Four cases of wound infection were reported in this series which represents 5.8%. Only one patient (1.4%) required a formal washout in the theatre. Three patients out of 33 TXA patients (9%) developed wound complications. There were two cases of wound dehiscence, one of which required negative pressure wound therapy (NPWT). One (3%) developed superficial wound infection, which responded to oral antibiotics.

Eight out of 36 non-TXA patients (22%) developed wound complications. Three (8.3%) had delayed wound healing, one deep infection had formal washout (2.8%), two superficial (5.6%) wound infection cases responded to oral antibiotics, and two cases (5.6%) of wound dehiscence, one of which required NPWT (Figure 1). The Chi-square tests revealed a significant statistical difference between the two groups (p=0.002) when comparing the incidence of wound complications.
The preoperative mean MOXFQ for all patients was 85.35 (SD±6.31) which was significantly improved to 18.15 (SD±13.64). The TXA group achieved better results compared to the non-TXA group (p=0.0130). The results of pre and postoperative MOXFQ for each group are reported in Table 3.

|                | Preoperative MOXFQ (SD) | Postoperative MOXFQ (SD) |
|----------------|-------------------------|--------------------------|
| TXA            | 86.31 (SD±5.33)         | 13.96 (SD±11.17)         |
| Non-TXA        | 84.46 (SD±6.98)         | 21.98 (SD±14.55)         |
| P-value        | 0.2234                  | 0.0130                   |
| 95% Confidence interval | -4.8548 to 1.1548      | 1.7447 to 14.2953        |

TABLE 3: Results of MOXFQ scores
MOXFQ: Manchester-Oxford foot questionnaire, SD: Standard deviation, TXA: Tranexamic acid

Discussion
Our study assessed the effect of TXA in ankle arthroplasty. There was no statistically significant difference with regard to blood loss (p=0.728). However, there was a significant effect on wound complications.
Total ankle replacement surgery has become an effective management option with more favorable results than ankle fusion [1]. Furthermore, recent advances in prosthetic designs have significantly improved the survival and short to midterm clinical and radiological outcomes. On the other hand, wound complications and surgical site infections remain major concerns with rates ranging from 0% to 13%, with diabetes, autoimmune diseases, smoking, and coronary and peripheral vascular disease as risk factors [4,5]. The ankle, when compared to hips and knees, has a thin, soft tissue coverage with no elaborate elasticity properties. Thus, the resultant swelling from intraoperative soft-tissue release and the bleeding from bone and blood vessels are not well accommodated by the small intra-articular volume [20].

Although using a tourniquet in TAR will significantly reduce intraoperative blood loss, the internal bleeding after releasing the tourniquet comes with an increased risk of postoperative swelling, pain, and wound complications. Furthermore, patients with no arterial disease usually have a rich vascular supply surrounding the ankle, and these blood vessels do not tolerate dislocation and subluxation, as in the case of THA or TKA [21]. Hence the shear forces can easily tear the branches of the anterior tibial, causing more bleeding and swelling [22]. Therefore, reducing hemarthrosis within the ankle joint may lead to a decrease in postoperative swelling, decreased pain, and increased range of motion due to the diminished potential for fibrosis [23].

Currently, most hip and knee surgeons are routinely using TXA to minimize the amount of intraoperative bleeding. Yuan et al. conducted a study in 2014 to see if TXA could heal the skin barrier using injured skin models and tight intercellular connections. They concluded that TXA might speed skin barrier healing and upregulate occludin induced by physicochemical damage to human skin using bioengineering technologies and immunohistochemical assays [24]. Björnín et al. [25] studied the effect of epsilon-aminocaproic acid and TXA on wound healing in white rats. Wounds injected with TXA had higher tensile strength than those pre-treated with epsilon-aminocaproic acid. Even when compared with the same ionic strength, similar results were obtained. Guerreiro et al. investigated the role of TXA in total knee arthroplasty in a randomized control trial [26]. Before the joint capsule was closed, 22 patients were given topical TXA. In the initial hours after introducing TXA, decreased pain and boosted flexion gain in addition to a reduction in bleeding were noted. Even though particular research revealed that TXA might have adverse effects on tendon repair [27], some authors advocated for TXA’s beneficial aspects on wound healing and skin regeneration. Björnín et al. highlighted that TXA has a good impact on the healing process and this effect is not due to the anti-fibrinolytic properties, as both are potent fibrinolytic inhibitors.

In addition, Gupta et al. [28] looked at the role of TXA in reducing wound infection in orthopedic patients after surgery. A total of 120 surgeries were included in the study, including spine, intertrochanteric fractures, hip hemaarthroplasty, and general trauma. Two of the 60 patients on TXA became infected, while four of the 60 patients who were not on TXA became infected. In their series, Mannan et al. [13] concluded that TXA improves hemostasis after deflating the tourniquet, and decreases the swelling and wound complications postoperatively. They also suggested that TXA is effective in reducing wound dehiscence rate, and the need for prolonged antibiotics. As elbows too are similar to ankles as they have thin, soft tissue coverage and small intra-articular volume.

In this study, we observed a significant reduction in postoperative wound complications in patients who received TXA. At the same time, there was no statistically significant difference in blood loss, transfusion rates, or incidence of pulmonary embolism and deep venous thrombosis. Although the two groups achieved significant improvement following TAR based on the MOXFQ results, the TXA group’s results were superior. The limitations of this study include its retrospective nature and the relatively small sample size.

Conclusions
Tranexamic acid is proven to be safe and effective in reducing postoperative bleeding and maintaining hemostasis after deflating tourniquet, thereby reducing swelling and wound complications like breakdown and dehiscence postoperatively. It has a positive impact on post-operative functional outcomes. Future studies are underway with a bigger sample size evaluating the role of TXA in wound healing after total ankle replacement.

Additional Information
Disclosures
Human subjects: Consent was obtained or waived by all participants in this study. Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial
relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. **Other relationships:** All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

**References**

1. Bonasia DE, Dettoni F, Fenmo II, Phisitkul P, Germano M, Amendola A: Total ankle replacement: why, when and how?. Iowa Orthop J. 2010, 30:119-130.

2. Lawton CD, Butler BA, Dekker RG 2nd, Prescott A, Kadakia AR: Total ankle arthroplasty versus ankle arthrodesis—a comparison of outcomes over the last decade. J Orthop Surg Res. 2017, 12:76. 10.1186/s13018-017-0376-1

3. Demetracopolous CA, Adams SB Jr, Queen RM, DeOrio JK, Nunley JA 2nd, Easley ME: Effect of age on outcomes in total ankle arthroplasty. Foot Ankle Int. 2015, 36:871-880. 10.1177/1071100715579177

4. Gougoulias N, Khanna A, Maffulli N: How successful are current ankle arthroplasty? A systematic review of the literature. Clin Orthop Relat Res. 2010, 468:199-208. 10.1007/s11999-009-0987-3

5. Zhou H, Yakovleva M, Shaw JJ, Patel A, Li X: In-patient trends and complications after total ankle arthroplasty in the United States. Orthopedics. 2016, 39:e74-e79. 10.3928/01477447-20151228-05

6. Elliott AD, Rookus TS: Anterior incision offloading for primary and revision total ankle replacement: a comparative analysis of two techniques. Open Orthop J. 2017, 11:678-686. 10.2174/1874325001711010678

7. Li Y, Bao BH, Jiang QZ, Wu HY: Complications in operative fixation of calcaneal fractures. Pak J Med Sci. 2016, 32:857-862. 10.12669/pjms.324.10225

8. Liu D, Dan M, Martinez-Martos S, Beller E: Blood management strategies in total knee arthroplasty. Knee Surg Relat Res. 2016, 28:179-187. 10.5792/krr.2016.28.3.179

9. Nozdo SR, Pavlesen S, Ritter C, Boyle KR: Tranexamic acid reduces perioperative blood loss and hemarthrosis in total ankle arthroplasty. Am J Orthop (Belle Mead NJ). 2018, 47: 10.12788/njo.2018.0063

10. Ishida K, Tsumura N, Kitagawa A, et al.: Intra-articular injection of tranexamic acid reduces not only blood loss but also knee joint swelling after total knee arthroplasty. Int Orthop. 2011, 35:1639-1645. 10.1007/s00264-010-1205-3

11. Huang F, Wu D, Ma G, Yin Z, Wang Q: The use of tranexamic acid to reduce blood loss and transfusion in major orthopedic surgery: a meta-analysis. J Surg Res. 2014, 186:518-527. 10.1016/j.jss.2013.08.020

12. Krohs CD, Sorensen R, Lange JE, Riise R, Bjerrens S, Brostad F: Tranexamic acid given into the wound reduces postoperative blood loss by half in major orthopaedic surgery. Eur J Surg Suppl. 2005, 57-61.

13. Mannan S, Ali M, Mazur L, Chin M, Fadulelmola A: The use of tranexamic acid in total elbow replacement to reduce post-operative wound infection. J Bone Jt Infect. 2018, 5:104-107. 10.7150/jbji.25610

14. Wiman B, Collen D: Molecular mechanism of physiological fibrinolysis. Nature. 1978, 272:549-550. 10.1038/272549a0

15. Kwaan HC, Astrup T: Tissue repair in presence of locally applied inhibitors of fibrinolysis. Exp Mol Pathol. 1969, 11:82-88. 10.1016/0014-4800(69)90072-0

16. Vincnck F, Vemylen J: Wound healing following dental extractions in rabbits: effects of tranexamic acid, warfarin anti-coagulation, and socket packing. J Dent Res. 1984, 63:646-649. 10.1007/bf02463502

17. Agha RA, Fowler AJ, Rajmohan S, Barai I, Orgill DP: Preferred reporting of case series in surgery; the PROCESS guidelines. Int J Surg. 2016, 36:319-325. 10.1016/j.ijsu.2016.06.025

18. Morley D, Jenkinson C, Doll H, Lavis G, Sharp R, Cooke P, Dawson J: The Manchester-Oxford foot questionnaire (MOXFQ): development and validation of a summary index score. Bone Joint Res. 2013, 2:66-69. 10.1302/2046-3758.24.2000147

19. Henriksen A, Carlsson A, Rydhholm U: What is a revision of total ankle replacement?. Foot Ankle Surg. 2011, 17:99-102. 10.1016/j.fas.2010.02.007

20. Draeger RW, Singh B, Parekh SG: Quantifying normal ankle joint volume: an anatomic study. Indian J Orthop. 2009, 43:72-75. 10.4103/0019-5413.45326

21. Gill LI: Challenges in total ankle arthroplasty. Foot Ankle Int. 2004, 25:195-207. 10.1177/1071100715579717

22. Taylor GI, Pan WR: Angiosomes of the leg: anatomic study and clinical implications. Plast Reconstr Surg. 1998, 102:599-616.

23. Nocelle S, Egidy CC, Cross MB, Gebauer M, Klauser W: Complication rates after total ankle arthroplasty in one hundred consecutive prostheses. Int Orthop. 2015, 39:1789-1794. 10.1007/s00264-013-1971-9

24. Yuan C, Wang XM, Yang LJ, Wu PL: Tranexamic acid accelerates skin barrier recovery and upregulates occludin in damaged skin. Int J Dermatol. 2014, 53:959-965. 10.1111/ijd.12099

25. Guerreiro JP, Badaro BS, Balbino JR, Danieli MV, Queiroz AO, Cataneo DC: Application of tranexamic acid in total knee arthroplasty - prospective randomized trial. Open Orthop J. 2017, 11:1049-1057. 10.2174/1874325001711011049

26. Şıhriş A, Gürğör PN, Uzun E, Erdem H, Çankaya S, Baş O: Local application of tranexamic acid affects tendon healing negatively in the late period. Eklem Hastalik Cerrahisi. 2018, 29:20-26. 10.5606/ehc.2018.56675

27. Björn G, Nilsson IM: The effect of anti-fibrinolytic agents on wound healing. Int J Oral Maxillofac Surg. 1988, 17:275-276. 10.1016/0901-5027(88)80056-0

28. Gupta Anil, Mohinder Singh, Prince Raina, et al.: Post-surgical wound care in orthopedics: role of tranexamic acid. J Evol Med Dent Sci. 2015, 4:5716-5720.